IMPACT THERAP-B (07630) bucked the broader market trend, surging more than 15%. As of press time, the stock was up 11.85% at HK$9.295, with a turnover of HK$53.443 million.
On the news front, on November 17, IMPACT THERAP-B announced that its independently developed innovative drug Senaparib (Paishuning®, overseas brand name Sepalna®) has officially received the final decision from the European Commission, approving its use for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
This approval was formally granted following the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency. Senaparib thus becomes the first China-originated PARP inhibitor approved in the EU for first-line maintenance treatment across the entire population of advanced ovarian cancer patients, marking another breakthrough for a domestically developed targeted innovative drug for ovarian cancer in the European market.
Comments